Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization

Yuri Kogan, Karin Halevi-Tobias, Moran Elishmereni, Stanimir Vuk-Pavlović, Zvia Agur

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Although therapeutic vaccination often induces markers of tumor-specific immunity, therapeutic responses remain rare. An improved understanding of patient-specific dynamic interactions of immunity and tumor progression, combined with personalized application of immune therapeutics would increase the efficacy of immunotherapy. Here, we developed a method to predict and enhance the individual response to immunotherapy by using personalized mathematical models, constructed in the early phase of treatment. Our approach includes an iterative real-time in-treatment evaluation of patient-specific parameters from the accruing clinical data, construction of personalized models and their validation, model-based simulation of subsequent response to ongoing therapy, and suggestion of potentially more effective patient-specific modified treatment. Using a mathematical model of prostate cancer immunotherapy, we applied our model to data obtained in a clinical investigation of an allogeneic whole-cell therapeutic prostate cancer vaccine. Personalized models for the patients who responded to treatment were derived and validated by data collected before treatment and during its early phase. Simulations, based on personalized models, suggested that an increase in vaccine dose and administration frequency would stabilize the disease in most patients. Together, our findings suggest that application of our method could facilitate development of a new paradigm for studies of in-treatment personalization of the immune agent administration regimens (P-trials), with treatment modifications restricted to an approved range, resulting in more efficacious immunotherapies.

Original languageEnglish (US)
Pages (from-to)2218-2227
Number of pages10
JournalCancer Research
Volume72
Issue number9
DOIs
StatePublished - May 1 2012

Fingerprint

Immunotherapy
Neoplasms
Therapeutics
Immunity
Prostatic Neoplasms
Theoretical Models
Cancer Vaccines
Tumor Biomarkers
Vaccination
Vaccines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization. / Kogan, Yuri; Halevi-Tobias, Karin; Elishmereni, Moran; Vuk-Pavlović, Stanimir; Agur, Zvia.

In: Cancer Research, Vol. 72, No. 9, 01.05.2012, p. 2218-2227.

Research output: Contribution to journalArticle

Kogan, Y, Halevi-Tobias, K, Elishmereni, M, Vuk-Pavlović, S & Agur, Z 2012, 'Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization', Cancer Research, vol. 72, no. 9, pp. 2218-2227. https://doi.org/10.1158/0008-5472.CAN-11-4166
Kogan, Yuri ; Halevi-Tobias, Karin ; Elishmereni, Moran ; Vuk-Pavlović, Stanimir ; Agur, Zvia. / Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization. In: Cancer Research. 2012 ; Vol. 72, No. 9. pp. 2218-2227.
@article{f8211cac4c93413cb62348dc7848e97c,
title = "Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization",
abstract = "Although therapeutic vaccination often induces markers of tumor-specific immunity, therapeutic responses remain rare. An improved understanding of patient-specific dynamic interactions of immunity and tumor progression, combined with personalized application of immune therapeutics would increase the efficacy of immunotherapy. Here, we developed a method to predict and enhance the individual response to immunotherapy by using personalized mathematical models, constructed in the early phase of treatment. Our approach includes an iterative real-time in-treatment evaluation of patient-specific parameters from the accruing clinical data, construction of personalized models and their validation, model-based simulation of subsequent response to ongoing therapy, and suggestion of potentially more effective patient-specific modified treatment. Using a mathematical model of prostate cancer immunotherapy, we applied our model to data obtained in a clinical investigation of an allogeneic whole-cell therapeutic prostate cancer vaccine. Personalized models for the patients who responded to treatment were derived and validated by data collected before treatment and during its early phase. Simulations, based on personalized models, suggested that an increase in vaccine dose and administration frequency would stabilize the disease in most patients. Together, our findings suggest that application of our method could facilitate development of a new paradigm for studies of in-treatment personalization of the immune agent administration regimens (P-trials), with treatment modifications restricted to an approved range, resulting in more efficacious immunotherapies.",
author = "Yuri Kogan and Karin Halevi-Tobias and Moran Elishmereni and Stanimir Vuk-Pavlović and Zvia Agur",
year = "2012",
month = "5",
day = "1",
doi = "10.1158/0008-5472.CAN-11-4166",
language = "English (US)",
volume = "72",
pages = "2218--2227",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization

AU - Kogan, Yuri

AU - Halevi-Tobias, Karin

AU - Elishmereni, Moran

AU - Vuk-Pavlović, Stanimir

AU - Agur, Zvia

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Although therapeutic vaccination often induces markers of tumor-specific immunity, therapeutic responses remain rare. An improved understanding of patient-specific dynamic interactions of immunity and tumor progression, combined with personalized application of immune therapeutics would increase the efficacy of immunotherapy. Here, we developed a method to predict and enhance the individual response to immunotherapy by using personalized mathematical models, constructed in the early phase of treatment. Our approach includes an iterative real-time in-treatment evaluation of patient-specific parameters from the accruing clinical data, construction of personalized models and their validation, model-based simulation of subsequent response to ongoing therapy, and suggestion of potentially more effective patient-specific modified treatment. Using a mathematical model of prostate cancer immunotherapy, we applied our model to data obtained in a clinical investigation of an allogeneic whole-cell therapeutic prostate cancer vaccine. Personalized models for the patients who responded to treatment were derived and validated by data collected before treatment and during its early phase. Simulations, based on personalized models, suggested that an increase in vaccine dose and administration frequency would stabilize the disease in most patients. Together, our findings suggest that application of our method could facilitate development of a new paradigm for studies of in-treatment personalization of the immune agent administration regimens (P-trials), with treatment modifications restricted to an approved range, resulting in more efficacious immunotherapies.

AB - Although therapeutic vaccination often induces markers of tumor-specific immunity, therapeutic responses remain rare. An improved understanding of patient-specific dynamic interactions of immunity and tumor progression, combined with personalized application of immune therapeutics would increase the efficacy of immunotherapy. Here, we developed a method to predict and enhance the individual response to immunotherapy by using personalized mathematical models, constructed in the early phase of treatment. Our approach includes an iterative real-time in-treatment evaluation of patient-specific parameters from the accruing clinical data, construction of personalized models and their validation, model-based simulation of subsequent response to ongoing therapy, and suggestion of potentially more effective patient-specific modified treatment. Using a mathematical model of prostate cancer immunotherapy, we applied our model to data obtained in a clinical investigation of an allogeneic whole-cell therapeutic prostate cancer vaccine. Personalized models for the patients who responded to treatment were derived and validated by data collected before treatment and during its early phase. Simulations, based on personalized models, suggested that an increase in vaccine dose and administration frequency would stabilize the disease in most patients. Together, our findings suggest that application of our method could facilitate development of a new paradigm for studies of in-treatment personalization of the immune agent administration regimens (P-trials), with treatment modifications restricted to an approved range, resulting in more efficacious immunotherapies.

UR - http://www.scopus.com/inward/record.url?scp=84860506962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860506962&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-11-4166

DO - 10.1158/0008-5472.CAN-11-4166

M3 - Article

C2 - 22422938

AN - SCOPUS:84860506962

VL - 72

SP - 2218

EP - 2227

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 9

ER -